Skip to main content
OpenTrials
Completed

NCT Number: NCT05832879

Telehealth Treatment for Opioid Use Disorders

This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yale School of Medicine

New Haven, Connecticut, 06520, United States

About this study

The primary objective of the study is to assess effects of enrollment in a comprehensive telehealth platform, in adults with moderate or severe opioid use disorder with a history of at least one opioid overdose. Adults with moderate or severe opioid use disorder with a history of at least one opioid overdose will be enrolled and the primary endpoint will be attendance at first appointment for medication for opioid use disorder at 30 days.

Secondary aims include assessing engagement in the first MOUD appointment at 90 days and self-report of the number of subsequent overdose events at 30 and 90 days. Exploratory aims include feasibility of intervention, readiness and intention to engage in treatment, acceptability and satisfaction of intervention, and comparison of MOUD engagement with data from previous in-person studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Can speak, read and write in English
  • Provision of signed and dated informed consent form
  • Have a history of at least one opioid overdose
  • Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
  • Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team
  • Can provide a working email address OR be willing to create one

Exclusion criteria

  • Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
  • Pregnancy
  • Known current suicide risk based on participant self-report
  • On parole or incarcerated at time of enrollment based on participant self-report

Treatment and study plan

OUD Telehealth Platform

Behavioral

The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users

Primary outcomes

  1. Attendance for MOUD

    Time frame: Up to 30 Days

    Overall attendance will be measured by attendance (yes or no) at the first buprenorphine appointment within 30 days of referral.

Secondary outcomes

  1. Engagement with MOUD

    Time frame: Up to 90 days

    Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of referral.

  2. Overdose Events at 30 Days

    Time frame: Up to 30 days

    A self-report of the number of subsequent overdose events at 30 days.

  3. Overdose Events at 90 Days

    Time frame: Up to 90 days

    A self-report of the number of subsequent overdose events at 90 days.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

A Pilot Study of Telehealth Treatment for Opioid Use Disorders

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 27, 2023
Registry last updated
Oct 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.